These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 18339883)

  • 21. Long-term phenotypic, functional and genetic stability of cancer-specific T-cell receptor (TCR) alphabeta genes transduced to CD8+ T cells.
    Hiasa A; Hirayama M; Nishikawa H; Kitano S; Nukaya I; Yu SS; Mineno J; Kato I; Shiku H
    Gene Ther; 2008 May; 15(9):695-9. PubMed ID: 18288212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presence of low dose of fludarabine in cultures blocks regulatory T cell expansion and maintains tumor-specific cytotoxic T lymphocyte activity generated with peripheral blood lymphocytes.
    Hegde U; Chhabra A; Chattopadhyay S; Das R; Ray S; Chakraborty NG
    Pathobiology; 2008; 75(3):200-8. PubMed ID: 18550918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy.
    Willemsen R; Chames P; Schooten E; Gratama JW; Debets R
    Cytometry A; 2008 Nov; 73(11):1093-9. PubMed ID: 18785268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy.
    Zandvliet ML; Falkenburg JH; Jedema I; Willemze R; Guchelaar HJ; Meij P
    J Immunother; 2009 Jun; 32(5):513-23. PubMed ID: 19609244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors.
    Kircher MF; Allport JR; Graves EE; Love V; Josephson L; Lichtman AH; Weissleder R
    Cancer Res; 2003 Oct; 63(20):6838-46. PubMed ID: 14583481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
    Jorritsma A; Bins AD; Schumacher TN; Haanen JB
    Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients.
    Rosenthal R; Groeper C; Bracci L; Adamina M; Feder-Mengus C; Zajac P; Iezzi G; Bolli M; Weber WP; Frey DM; von Holzen U; Oertli D; Heberer M; Spagnoli GC
    J Immunother; 2009 Apr; 32(3):252-61. PubMed ID: 19242375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer.
    Dobrzanski MJ; Reome JB; Hylind JC; Rewers-Felkins KA; Abulsamad K; Adams SL
    Clin Immunol; 2008 Aug; 128(2):205-18. PubMed ID: 18511346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
    Mueller K; Schweier O; Pircher H
    Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
    Stastny MJ; Brown CE; Ruel C; Jensen MC
    J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-15 favors the expansion of central memory CD8+ T cells in ex vivo generated, antileukemia human cytotoxic T lymphocyte lines.
    Daudt L; Maccario R; Locatelli F; Turin I; Silla L; Montini E; Percivalle E; Giugliani R; Avanzini MA; Moretta A; Montagna D
    J Immunother; 2008 May; 31(4):385-93. PubMed ID: 18391757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
    Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
    Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.
    Godet Y; Moreau-Aubry A; Guilloux Y; Vignard V; Khammari A; Dreno B; Jotereau F; Labarriere N
    J Exp Med; 2008 Oct; 205(11):2673-82. PubMed ID: 18936238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.